KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Operating Expenses: 2014-2024

Historic Operating Expenses for Aurinia Pharmaceuticals (AUPH) over the last 11 years, with Dec 2024 value amounting to $239.8 million.

  • Aurinia Pharmaceuticals' Operating Expenses fell 21.96% to $43.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $195.8 million, marking a year-over-year decrease of 22.62%. This contributed to the annual value of $239.8 million for FY2024, which is 10.25% down from last year.
  • Per Aurinia Pharmaceuticals' latest filing, its Operating Expenses stood at $239.8 million for FY2024, which was down 10.25% from $267.2 million recorded in FY2023.
  • Aurinia Pharmaceuticals' Operating Expenses' 5-year high stood at $267.2 million during FY2023, with a 5-year trough of $154.4 million in FY2020.
  • Its 3-year average for Operating Expenses is $250.8 million, with a median of $245.5 million in 2022.
  • In the last 5 years, Aurinia Pharmaceuticals' Operating Expenses soared by 69.19% in 2020 and then dropped by 10.25% in 2024.
  • Aurinia Pharmaceuticals' Operating Expenses (Yearly) stood at $154.4 million in 2020, then surged by 46.59% to $226.3 million in 2021, then rose by 8.47% to $245.5 million in 2022, then increased by 8.84% to $267.2 million in 2023, then declined by 10.25% to $239.8 million in 2024.